Kazuhiko Nakagawa
0000-0003-1284-9776
Publication & Citation Trends
Publications
1,437 total
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB–IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial
Cited by 722
OpenAlex
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study PDF
Cited by 2,444
OpenAlex
CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated <i>EGFR</i>-Mutated Advanced Non–Small-Cell Lung Cancer PDF
Cited by 778
OpenAlex
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Cited by 1,193
OpenAlex
Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer
Cited by 996
OpenAlex
Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
Cited by 905
OpenAlex
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer PDF
Cited by 3,195
OpenAlex
Research Topics
Lung Cancer Treatments and Mutations
(873)
Lung Cancer Research Studies
(376)
Lung Cancer Diagnosis and Treatment
(262)
Colorectal Cancer Treatments and Studies
(218)
Cancer Immunotherapy and Biomarkers
(215)
Affiliations
AstraZeneca (United Kingdom)
Hebron University
Tokyo Medical and Dental University
Toho University
Boehringer Ingelheim (Germany)